{
    "nct_id": "NCT03680521",
    "official_title": "A Phase 2 Study of Sitravatinib in Combination With Nivolumab in Patients Undergoing Nephrectomy for Locally-Advanced Clear Cell Renal Cell Carcinoma",
    "inclusion_criteria": "1. Imaging results consistent with locally-advanced RCC\n2. Candidate for partial or complete nephrectomy as part of treatment plan.\n3. Measurable disease per RECIST version 1.1.\n4. ECOG performance status 0 or 1.\n5. Adequate bone marrow and organ function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Prior systemic anti-tumor treatment for RCC.\n2. Patients who are receiving any other investigational agents.\n3. Clinical status indicating that immediate surgery (within 6 weeks) is warranted regardless of whether neoadjuvant therapy is to be administered, as assessed by the treating surgeon.\n4. Inability to undergo baseline tumor biopsy.\n5. Active or prior documented autoimmune or immunocompromising conditions.\n6. Uncontrolled hypertension.",
    "miscellaneous_criteria": ""
}